Bose S Kochupurakkal (Bose Kochupurakkal)

Publication Activity (10 Years)

Years Active: 2023-2024
Publications (10 Years): 6

Top Topics

Locally Advanced

Placebo Controlled

Top Venues

JCO precision oncology

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Clinical cancer research : an official journal of the American Association for Cancer Research

Molecular cancer therapeutics

This page only lists publications with an associated author ORCID identifier.

Publications

Panagiotis A Konstantinopoulos, Su-Chun Cheng, Elizabeth K Lee, Alexandre Andre Balieiro Anastacio da Costa, Doga C Gulhan, Andrea E Wahner Hendrickson, Bose S Kochupurakkal, David L Kolin, Elise C Kohn, Joyce F Liu, Richard T Penson, Elizabeth H Stover, Jennifer Curtis, Hannah Sawyer, Madeline Polak, Dipanjan Chowdhury, Alan D' Andrea, Anniina Färkkilä, Geoffrey I Shapiro, Ursula A Matulonis
Randomized Phase II Study of Gemcitabine With or Without ATR Inhibitor Berzosertib in Platinum-Resistant Ovarian Cancer: Final Overall Survival and Biomarker Analyses. JCO precision oncology 8 (2024)
Panagiotis A Konstantinopoulos, Su-Chun Cheng, Elizabeth K Lee, Alexandre Andre Balieiro Anastacio da Costa, Doga C Gulhan, Andrea E Wahner Hendrickson, Bose S Kochupurakkal, David L Kolin, Elise C Kohn, Joyce F Liu, Richard T Penson, Elizabeth H Stover, Jennifer Curtis, Hannah Sawyer, Madeline Polak, Dipanjan Chowdhury, Alan D' Andrea, Anniina Färkkilä, Geoffrey I Shapiro, Ursula A Matulonis
Randomized Phase II Study of Gemcitabine With or Without ATR Inhibitor Berzosertib in Platinum-Resistant Ovarian Cancer: Final Overall Survival and Biomarker Analyses. JCO precision oncology 8 (2024)
Panagiotis A Konstantinopoulos, Su-Chun Cheng, Elizabeth K Lee, Alexandre Andre Balieiro Anastacio da Costa, Doga C Gulhan, Andrea E Wahner Hendrickson, Bose S Kochupurakkal, David L Kolin, Elise C Kohn, Joyce F Liu, Richard T Penson, Elizabeth H Stover, Jennifer Curtis, Hannah Sawyer, Madeline Polak, Dipanjan Chowdhury, Alan D' Andrea, Anniina Färkkilä, Geoffrey I Shapiro, Ursula A Matulonis
Randomized Phase II Study of Gemcitabine With or Without ATR Inhibitor Berzosertib in Platinum-Resistant Ovarian Cancer: Final Overall Survival and Biomarker Analyses. JCO precision oncology 8 (2024)
Brandon M Huffman, Hanrong Feng, Kalindi Parmar, Junning Wang, Kevin S Kapner, Bose S Kochupurakkal, David B Martignetti, Golbahar Sadatrezaei, Thomas A Abrams, Leah H Biller, Marios Giannakis, Kimmie Ng, Anuj K Patel, Kimberley J Perez, Harshabad Singh, Douglas A Rubinson, Benjamin L Schlechter, Elizabeth Andrews, Alison M Hannigan, Stanley Dunwell, Zoe Getchell, Srivatsan Raghavan, Brian M Wolpin, Caroline Fortier, Alan D' Andrea, Andrew J Aguirre, Geoffrey I Shapiro, James M Cleary
A Phase 1 Expansion Cohort Study Evaluating the Safety and Efficacy of the CHK1 Inhibitor LY2880070 with Low-Dose Gemcitabine in Metastatic Pancreatic Adenocarcinoma Patients. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Matthew A Ingham, Jacob B Allred, Li Chen, Biswasjit Das, Bose S Kochupurakkal, Katherine Gano, Suzanne George, Steven Attia, Melissa A Burgess, Mahesh Seetharam, Sosipatros A Boikos, Nam Q Bui, James L Chen, Julia L Close, Gregory M Cote, Premal H Thaker, Susan Percy Ivy, Sminu Bose, Alan D' Andrea, Adrian Mariño-Enriquez, Geoffrey I Shapiro, Gary K Schwartz
Phase II Study of Olaparib and Temozolomide for Advanced Uterine Leiomyosarcoma (NCI Protocol 10250). Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Elizabeth Pan, Wanling Xie, Archana Ajmera, Arlene Araneta, Christina A M Jamieson, Edmund Folefac, Arif Hussain, Christos E Kyriakopoulos, Adam C Olson, Mamta Parikh, Rahul A Parikh, Biren Saraiya, Susan Percy Ivy, Eliezer Van Allen, Neal I Lindeman, Bose S Kochupurakkal, Geoffrey I Shapiro, Rana R McKay
A Phase I Study of Combination Olaparib and Radium-223 in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) with Bone Metastases (COMRADE). Molecular cancer therapeutics (2023)